Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer

Hye Jin Choi, Nam Kyu Kim, Ki Chang Keum, Seong Ha Cheon, Sang Jun Shin, Seung Hyuk Baik, Jae Hee Choen, Sun Young Rha, Jae Kyung Roh, Hei Cheul Jeung, Hyun Cheol Chung, Joong Bae Ahn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.

Original languageEnglish
Pages (from-to)361-366
Number of pages6
JournalRadiotherapy and Oncology
Volume87
Issue number3
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

irinotecan
Chemoradiotherapy
Rectal Neoplasms
Appointments and Schedules
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Choi, Hye Jin ; Kim, Nam Kyu ; Keum, Ki Chang ; Cheon, Seong Ha ; Shin, Sang Jun ; Baik, Seung Hyuk ; Choen, Jae Hee ; Rha, Sun Young ; Roh, Jae Kyung ; Jeung, Hei Cheul ; Chung, Hyun Cheol ; Ahn, Joong Bae. / Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. In: Radiotherapy and Oncology. 2008 ; Vol. 87, No. 3. pp. 361-366.
@article{e6ebf4bba19c49a69040e7dfca1c9846,
title = "Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer",
abstract = "S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.",
author = "Choi, {Hye Jin} and Kim, {Nam Kyu} and Keum, {Ki Chang} and Cheon, {Seong Ha} and Shin, {Sang Jun} and Baik, {Seung Hyuk} and Choen, {Jae Hee} and Rha, {Sun Young} and Roh, {Jae Kyung} and Jeung, {Hei Cheul} and Chung, {Hyun Cheol} and Ahn, {Joong Bae}",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.radonc.2008.04.001",
language = "English",
volume = "87",
pages = "361--366",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. / Choi, Hye Jin; Kim, Nam Kyu; Keum, Ki Chang; Cheon, Seong Ha; Shin, Sang Jun; Baik, Seung Hyuk; Choen, Jae Hee; Rha, Sun Young; Roh, Jae Kyung; Jeung, Hei Cheul; Chung, Hyun Cheol; Ahn, Joong Bae.

In: Radiotherapy and Oncology, Vol. 87, No. 3, 01.06.2008, p. 361-366.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer

AU - Choi, Hye Jin

AU - Kim, Nam Kyu

AU - Keum, Ki Chang

AU - Cheon, Seong Ha

AU - Shin, Sang Jun

AU - Baik, Seung Hyuk

AU - Choen, Jae Hee

AU - Rha, Sun Young

AU - Roh, Jae Kyung

AU - Jeung, Hei Cheul

AU - Chung, Hyun Cheol

AU - Ahn, Joong Bae

PY - 2008/6/1

Y1 - 2008/6/1

N2 - S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.

AB - S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.

UR - http://www.scopus.com/inward/record.url?scp=46549084526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46549084526&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2008.04.001

DO - 10.1016/j.radonc.2008.04.001

M3 - Article

C2 - 18439695

AN - SCOPUS:46549084526

VL - 87

SP - 361

EP - 366

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -